Researchers Submit Patent Application, "Mesothelin-Targeted Cd40 Agonistic Multispecific Antibody Constructs For The Treatment Of Solid Tumors", for Approval (USPTO 20240150481).
In: Immunotherapy Weekly, 2024-05-27, S. 1776-1776
serialPeriodical
Zugriff:
A patent application has been submitted for a new antibody construct that targets solid tumors. The construct aims to improve the effectiveness of anti-tumor treatments while minimizing side effects. It consists of two specific antibodies, one that activates CD40 signaling and another that targets a protein found on cancer cells. The application provides detailed information on the amino acid sequences used in the construct, which could have implications for the development of new immunotherapies for solid cancers. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Mesothelin-Targeted Cd40 Agonistic Multispecific Antibody Constructs For The Treatment Of Solid Tumors", for Approval (USPTO 20240150481).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-05-27, S. 1776-1776 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|